Seattle, WA | December 16, 2014
FOR IMMEDIATE RELEASE: SEATTLE, Dec. 16, 2014: A consultant for the international vaccine community who has had a long career in research and development, Michel De Wilde, Ph.D., has joined the IDRI (Infectious Disease Research Institute) Board of Directors, comprised of international leaders in industry and academia. De Wilde was among the first to use recombinant DNA technology in the industry and has contributed to the discovery and development of a number of vaccines.
“As IDRI continues to extend its reach into the global health vaccine market, developing vaccines of our own design and collaborating with others, Michel’s expertise in this field will be increasingly important,” said Steven G. Reed, Ph.D., IDRI Founder, President and Chief Scientific Officer.
From 2001 through 2013, De Wilde was Senior Vice President, Research & Development, at Sanofi Pasteur, the human vaccines division of Sanofi, where he supervised a broad portfolio of discovery and development projects, including the first Dengue vaccine that recently successfully completed phase 3 During his tenure at Sanofi Pasteur, De Wilde drove the development and licensure by the U.S. Food and Drug Administration of a number of products, including the first tetravalent meningococcal conjugate, the first prototype H5 pandemic vaccine and the first intradermal influenza vaccine, Intanza, which was also licensed by the European Medicines Agency. He also oversaw the licensure, under accelerated approval, of a new high-dose formulation of an influenza vaccine, which demonstrated superior efficacy to conventional vaccines in clinical trials. De Wilde was also instrumental in driving the acquisition of and defining the integration model for two biotech companies, Acambis and VaxDesign.
“Creating new or better vaccines for infectious diseases is one of the most important steps in improving global health, as so many diseases that create the biggest burden do not currently have effective vaccines,” said De Wilde. “I’m pleased to join the IDRI board to do my part to support IDRI’s mission of creating new products for diseases of global importance.”
Prior to joining Sanofi Pasteur, De Wilde was at SmithKline Beecham Biologicals (now GSK Vaccines) in Belgium. He joined the group in 1978 as a research scientist and subsequently held positions of increasing responsibility to become Vice President, Research & Development, heading a team active in all aspects of preclinical vaccine development.
De Wilde received his degree in chemistry from the Free University of Brussels in 1971, followed by a Ph.D. in biochemistry in 1976. He carried out postdoctoral work at the University of Wisconsin, Madison (U.S.) and the University of Ghent (Belgium).
As a non-profit global health organization, IDRI (Infectious Disease Research Institute) takes a comprehensive approach to combat infectious diseases, combining the high-quality science of a research organization with the product development capabilities of a biotech company to create new diagnostics, drugs and vaccines. IDRI combines passion for improving human health with the understanding that it is not just what our scientists know about disease, but what we do to change its course that will have the greatest impact. Founded in 1993, IDRI has 125 employees headquartered in Seattle with nearly 100 partners/collaborators around the world. For more information, visit www.idri.org.
IDRI: Lee Schoentrup | 206.858.6064 | email@example.com